

About Us

Talisman Therapeutics is a neurodegenerative disease drug discovery company, based on the Babraham Research Campus in Cambridge UK. We are committed to transforming the discovery of treatments for neurodegenerative disease, with a focus in dementia. Our novel human stem cell models of dementia provide a transformative platform for rapid and relevant target identification and validation, significantly accelerating drug discovery. Talisman's primary goal is the exploitation of these systems to identify novel pharmacological treatments for neurodegenerative diseases, including Alzheimer's disease, through our external collaborative work and through our in-house drug discovery programme.


Our Science

Talisman uses novel, proprietary human stem cell models of neurodegenerative disease. This enables rapid and relevant target identification and validation, as well as testing of candidate therapeutics. This approach significantly accelerates drug discovery.

Our technology transforms the discovery of new disease-modifying treatments by avoiding the limitations of current neurological drug discovery approaches. Human stem cells are used to produce disease-relevant neurons and glial cells that replicate the different aspects of neurodegenerative disease, offering several different phases of the disease to target therapeutically. By using human stem cell-based models early in the drug discovery process, we identify compounds that have much greater relevance to the disease process in the part of the human brain affected by the disease.

Cell & molecular biology of neurodegeneration

Alzheimer's disease is the most common neurological disease, affecting half of the World's population over 85. The World Alzheimer Report estimated that the \$604bn (£388bn) costs associated with dementia in 2010 amounted to more than one percent of the world's gross domestic product. About 70% of these costs occur in Western Europe and North America.



There are no disease-modifying drugs currently available to treat the initiation or progression of AD, with currently approved products only providing temporary symptomatic relief.

There is an immediate unmet need for the development of new treatments that target the underlying causes of Alzheimer's disease and allow early intervention before irreversible pathological changes occur. Meeting this need is a focus of Talisman's work.

In-house drug discovery programmes

Alzheimer's disease: endolysosome and autophagy modulation

Neurodegenerative disease spreading

Neuroinflammation and neuron:microglia interactions